Abstract 【Objective】To explore the clinical efficacy of recombinant human endostatin (ES) combined with NP regimen (vinorelbine+cisplatin) in the treatment of recurrent and metastatic nasopharyngeal carcinoma. 【Methods】A total of 82 patients with recurrent and metastatic nasopharyngeal carcinoma admitted to Shanghai Shuguang Hospital were selected as the research objects. According to the treatment plan, they were divided into the observation group and the control group. There were 40 patients in the control group who were treated with a single NP regimen, while 42 patients in the observation group were treated with NP regimen combined with ES. Both groups of patients were evaluated for efficacy and adverse drug reactions after 4 cycles of treatment. The 1-year survival rate of the two groups of patients was followed-up and recorded. 【Results】The disease control rate of the observation group was 90.47%, which was higher than that of the chemotherapy group (70.00%) (P<0.05). Most patients in the two groups had mild adverse reactions of grade I to II. There was no significant difference in the incidence of various adverse reactions in the two groups (P>0.05). In the control group, 21 patients died and the 1-year survival rate was 47.50% with the survival period of 4 to 8 months. While 13 patients died in the observation group showing he 1-year survival rate was 69.05%with the survival period was 7 to 11 months. There was a statistically significant difference in survival curves between the observation group and the control group (P<0.05). 【Conclusion】ES combined with NP regimen for patients with recurrent and metastatic advanced nasopharyngeal carcinoma can effectively improve the patient's disease control rate, prolong the patient's life cycle and have good safety.
CHEN Qi,CHEN Xuan,YOU Lan, et al. Efficacy of Recombinant Human Endostatin Combined with NP Regimen in Treatment of Recurrent and Metastatic Nasopharyngeal Carcinoma[J]. JOURNAL OF CLINICAL RESEARCH, 2021, 38(12): 1771-1773.
[1] 陈星睿,李登科,黄仲曦,等. EBV阳性人鼻咽癌细胞外泌体促进淋巴管新生与鼻咽癌淋巴结转移[J].南方医科大学学报,2020,40(12):1776-1783.
[2] LASTRUCCI L.Late toxicity, evolving radiotherapy techniques, and quality of life in nasopharyngeal carcinoma[J].Radiol Med,2017,122(4):303-308.
[3] LUNG R W, HAU P M, YU K H, et al. EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma[J].J Pathol,2018,244(4):394-407.
[4] 杨琛. 重组人血管内皮抑制素联合同步放化疗治疗鼻咽癌的疗效观察[J].中国现代医学杂志,2017,27(3):74-78.
[5] 曹淑琴,朱朝勇,张宽. 重组人血管内皮抑制素结合放化疗对鼻咽癌临床疗效、预后及血清血管内皮生长因子的影响[J].中国老年学杂志,2017,37(17):4290-4292.
[6] 中国抗癌协会鼻咽癌专业委员会,李金高,陈晓钟,等. 鼻咽癌复发、转移诊断专家共识[J].中华放射肿瘤学杂志,2018,27(1):7-15.
[7] EISENHAUER E A.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009, 45(2):228-247.
[8] TROTTI A, COLEVAS A D, SETSER A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment[J].Semin Radiat Oncol,2003,13(3):176-181.
[9] HONG M, TANG K, QIAN J, et al. Immunotherapy for EBV-associated nasopharyngeal carcinoma[J].Crit Rev Oncog,2018,23(3-4):219-234.
[10] 张伟.重组人血管内皮抑制素联合调强放疗治疗局部晚期低危鼻咽癌随机对照研究[J].海南医学,2016,27(23):3854-3856.
[11] 廖加群,薛英波,吴坤励,等. 卡培他滨联合重组人血管内皮抑制素治疗复发和转移鼻咽癌临床观察[J].中华肿瘤防治杂志,2019,26(16):1192-1195.
[12] 李宇,李燕娴,王茗,等. 重组人血管内皮抑制素联合放化疗治疗局部区域晚期鼻咽癌的安全性及近期疗效评估[J].肿瘤药学,2018,8(4):560-565.
[13] 潘欢,滕弥明,董洪敏,等. 重组人血管内皮抑制素窗口期联合化疗治疗晚期大肠癌的临床疗效[J].中国肿瘤临床,2020,47(8):402-406.
[14] 油杰,王新龙,毕蕴珠. 鼻咽癌靶向肽修饰的rES对鼻咽癌裸鼠移植瘤生长的影响[J].西部医学,2020,32(9):1304-1309.
2021, Vol. 38 
